Neoplasma Vol.69, No.4, p.832

Neoplasma Vol.69, No.4, p.832–840, 2022

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.69, No.4, p.832–840, 2022
Title: LIMD2 promotes tumor proliferation, invasion, and epithelial-mesenchymal transition in clear cell renal cell carcinoma
Author: Qi-Yu Zhong, Ying-Wei Xie, Zhi-Liang Chen, Yu-Qing Chen, Yue-Xin Liu, Wen-Lian Xie, Wei Yan

Abstract: LIMD2 was found upregulated in various tumors and metastatic samples and associated with a poor prognosis. But the role of LIMD2 in clear cell renal cell carcinoma (ccRCC) remains elusive. The expression of LIMD2 in ccRCC was analyzed using cohort data downloaded from TCGA and ICGC databases. In vitro and in vivo experiments were then conducted to study the biological role of LIMD2 in ccRCC and explore the possible mechanism. The results indicated that LIMD2 was overexpressed and correlated with a poor outcome in ccRCC. LIMD2 promoted the malignancy of ccRCC both in vitro and in vivo. LIMD2 induced epithelial-mesenchymal transition (EMT) via activating the ILK/Akt pathway in ccRCC. In conclusion, LIMD2 is overexpressed and promotes proliferation, invasion, and EMT in ccRCC, which may serve as a potential novel therapeutic target for ccRCC.

Keywords: LIM domain protein 2 (LIMD2); epithelial-mesenchymal transition (EMT); clear cell renal cell carcinoma (ccRCC); proliferation; invasion
	Published online: 09-May-2022
Year: 2022, Volume: 69, Issue: 4	Page From: 832, Page To: 840
doi:10.4149/neo_2022_211130N1701
	download file

Aepress.sk